Invesco Biotechnology & Genome ETF
PBE
68 hedge funds and large institutions have $55M invested in Invesco Biotechnology & Genome ETF in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
16% more capital invested
Capital invested by funds: $47.5M → $55M (+$7.57M)
2.7% more ownership
Funds ownership: 20.57% → 23.27% (+2.7%)
0% more funds holding
Funds holding: 68 → 68 (0)
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$5.82M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.77M |
| 4 |
VF
Virtu Financial
New York
|
+$788K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$645K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.26M |
| 2 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$1.46M |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$796K |
| 4 |
SG Americas Securities
New York
|
-$593K |
| 5 |
Jane Street
New York
|
-$501K |
PBE Hedge Fund Activity: Q1 2017 in Review
68 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2017, worth a combined $55M — up 16% from $47.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PBE positions and 6 closed out — a net gain of 1 holder — while 15 added to existing stakes and 25 trimmed.
The largest buyer was Stifel Financial, adding an estimated $5.82M. The largest seller was Goldman Sachs, cutting an estimated $2.26M.
- 68 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $55M of Invesco Biotechnology & Genome ETF stock for Q1 2017, up 16% quarter-over-quarter.
- 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2017 and 6 closed out, a net change of +1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2017 was Stifel Financial, an estimated $5.82M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2017 was Goldman Sachs, an estimated $2.26M sold.
Based on aggregated 13F filings for Q1 2017.